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OBJECTIVE— Obesity predisposes individuals to congestive heart failure (CHF) and car-
diovascular disease (CVD). Leptin regulates energy homeostasis, is elevated in obesity, and
influences ventricular and vascular remodeling. We tested the hypothesis that leptin levels are
associated with greater risk of CHF, CVD, and mortality in elderly individuals.
RESEARCH DESIGN AND METHODS— We evaluated 818 elderly (mean age 79
years, 62% women) Framingham Study participants attending a routine examination at which
plasma leptin was assayed.
RESULTS— Leptin levels were higher in women and strongly correlated with BMI (P 
0.0001). On follow-up (mean 8.0 years), 129 (of 775 free of CHF) participants developed CHF,
187 (of 532 free of CVD) experienced a first CVD event, and 391 individuals died. In multiva-
riable Cox regression models adjusting for established risk factors, log-leptin was positively
associated with incidence of CHF and CVD (hazard ratio [HR] per SD increment 1.26 [95% CI
1.03–1.55] and 1.28 [1.09–1.50], respectively). Additional adjustment for BMI nullified the
association with CHF (0.97 [0.75–1.24]) but only modestly attenuated the relation to CVD
incidence (1.23 [1.00–1.51], P 0.052). We observed a nonlinear, U-shaped relation between
log-leptin and mortality (P 0.005 for quadratic term) with greater risk of death evident at both
low and high leptin levels.
CONCLUSIONS— In our moderate-sized community-based elderly sample, higher circu-
lating leptin levels were associated with a greater risk of CHF and CVD, but leptin did not provide
incremental prognostic information beyond BMI. Additional investigations are warranted to
elucidate the U-shaped relation of leptin to mortality.
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E xcess adiposity is a key risk factor forcongestive heart failure (CHF) (1) andcardiovascular disease (CVD) (2), in
part because it is a fundamental precursor of
several vascular risk factors including high
blood pressure, dyslipidemia, and impaired
glucose homeostasis. Increased BMI is often
used as a surrogate measure of excess adi-
posity. However, BMI reflects the combined
mass of adipose and nonadipose tissue (in-
cluding muscles and bones). Therefore, lep-
tin, an anorexogenic hormone that is
predominantly produced in adipose tissue,
may be a better risk marker for CVD than
current BMI.
Several lines of evidence indicate a pu-
tative role for leptin in cardiac (3) and vas-
cular remodeling (4,5), although reports are
divided on whether leptin has predomi-
nantly adverse or beneficial effects on the
heart (6,7) and the vascular system (4,8,9).
Likewise, clinical studies on the association
with CVD have yielded inconsistent results
(10,11).
Interestingly, previous studies sug-
gested that leptin levels are not only deter-
mined by the current adipose tissue volume
but also by the weight history of an individ-
ual (12). Leptin might, therefore, be a better
marker of CVD risk than current BMI, par-
ticularly in normal-weight individuals with
a history of obesity, who might have sub-
clinical CVD (due to antecedent obesity).
Conversely, because obesity is associated
with relative leptin resistance that often per-
sists after weight reduction, “current” leptin
levels may misclassify the biological effects
of leptin exposure, leaving BMI with a
stronger association to CVD outcomes (rel-
ative to leptin).
On the basis of the clinical and experi-
mental data summarized above, we hypoth-
esized that leptin levels are associated with
the incidence of CHF, CVD, and all-cause
mortality in elderly individuals. We tested
this hypothesis by relating leptin levels to
the occurrence of CVD (including CHF)
and death prospectively in a moderate-sized
elderly community-based sample; we as-
sessed specifically whether leptin levels of-
fer incremental prognostic information over
established risk factors and BMI. We also
sought to examine the cross-sectional clini-
cal correlates of leptin and evaluated
whether leptin correlates with measures of
past BMI (i.e., serves as an indicator of an
individual’s weight history).
RESEARCH DESIGN AND
METHODS— The design and the se-
lection criteria of the Framingham Heart
Study have been published elsewhere
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(13). Participants in the original cohort
are seen in the Heart Study clinic every 2
years. At each examination, participants
undergo laboratory testing for CVD risk
factors, anthropometry, and an examina-
tion by a physician that includes a stan-
dardized medical history and a physical
examination. All attendees at the 22nd ex-
amination cycle of the original cohort (re-
ferred to as the “index” examination; n
1,173) were eligible for the present inves-
tigation; we excluded individuals with
nonavailable leptin levels (n 355). After
exclusions, 818 participants remained el-
igible for the analysis of clinical correlates
and relations to all-cause mortality. For
analyses of new-onset CHF, we excluded
43 individuals with prevalent CHF so that
775 remained eligible. For analyses of
first CVD events the participants with
prevalent CVD were excluded (n 286),
which left 532 eligible. All participants
provided written informed consent, and
the study protocol was approved by the
institutional review board at the Boston
University Medical Center.
Leptin assay
At examination cycle 22, blood was drawn
from nonfasting participants, usually be-
tween 1:00 and 2:00 P.M. Plasma leptin lev-
els were measured using a commercial
radioimmunoassay (Linco Research, St.
Louis, MO). The interassay coefficient of
variation ranged from 3.0 to 6.2%. The
lower sensitivity limit was 0.5 ng/ml.
Definitions of outcome events
All Heart Study participants are under
continuous surveillance for the incidence
of CVD (including CHF) and death. Out-
come events are adjudicated by a team of
three physicians who reviews all relevant
medical information, hospitalization
records, and physician office visits using
standardized criteria. A separate group
consisting of neurologists reviews and ad-
judicates all suspected cerebrovascular
events. Criteria for CVD have been pub-
lished and include coronary heart disease
(CHD) (recognized and unrecognized
myocardial infarction, coronary insuffi-
ciency, angina, and CHD death), cerebro-
vascular disease (stroke and transient
ischemic attack), intermittent claudica-
tion, and CHF (14). A diagnosis of CHF
requires the presence of at least two major
criteria or one major and two minor cri-
teria in the absence of a condition that can
explain the findings. The same definitions
have been used in the Framingham Heart
Study over the years.
In our primary analyses, we focused
on three end points: incident CHF, CVD,
and total mortality. In secondary analy-
ses, we related leptin with incident “hard”
CVD, a composite end point that includes
fatal and nonfatal myocardial infarction,
coronary insufficiency, stroke, or CHF.
Statistical analyses
Given a right-skewed distribution, leptin
levels were logarithmically transformed.
We evaluated the correlation of log-leptin
with BMI measured at the index examina-
tion, in the decade preceding the exami-
nation and over the interval of 10–20
years preceding the index examination
(average of available values for the respec-
tive decades). Next, we evaluated the
clinical correlates of log-leptin using
multivariable linear regression. Eligible
covariates included age, sex, BMI, systolic
and diastolic blood pressure, antihyper-
tensive treatment, total-to-HDL choles-
terol ratio, triglycerides, diabetes,
smoking, and prevalent CVD.
Separate analyses were conducted for
each of the three outcomes. Analysis dem-
onstrated a striking sexual dimorphism in
leptin levels, as reported previously (15).
Therefore, we standardized log-leptin val-
ues separately within sex. We performed
pooled sex analyses relating sex-
standardized log-leptin to the incidence
of outcome events because we did not ob-
serve effect modification by sex (P 0.75
for interactions for all three outcomes).
We evaluated the cumulative inci-
dence of outcome events for leptin levels
greater than or equal to versus less than
the sex-specific median value. The as-
sumption of proportionality of hazards
was confirmed. We used Cox regression
to relate log-leptin to each outcome. Two
sets of models were evaluated: 1) with ad-
justment for established risk factors; and
2) with additional adjustment for BMI.
We built models using this hierarchical
schema because leptin is strongly corre-
lated with BMI and also to assess the in-
cremental information provided by leptin
over BMI alone. Covariates in the first
model evaluating CHF incidence and
mortality included age, sex, total/HDL
cholesterol, diabetes, systolic and dia-
stolic blood pressure, antihypertensive
treatment, current smoking, history of
atrial fibrillation, and prevalent CVD. For
analyses of CVD incidence, covariates
were similar with the exception that par-
ticipants with prevalent CVD were ex-
cluded. To gain insights into potential
nonlinearity of associations between lep-
tin and risk of outcomes, we examined
generalized additive models using penal-
ized splines.
We tested for effect modification by
age, hypertension status, and obesity sep-
arately for each of the outcomes. In sec-
ondary analyses, we related leptin levels
to incidence of a first hard CVD event on
follow-up (covariates as noted above for
analyses of CVD). In secondary analyses,
we assessed the association of leptin with
CHF, CVD, and mortality in individuals
with and without a history of obesity (de-
fined as BMI30 kg/m2 at any time in the
25 years preceding baseline examination
cycle 22 at which leptin was assayed).
P  0.05 was used to indicate statis-
tical significance.
RESULTS— The baseline characteris-
tics of our elderly study sample are shown
in Table 1. Three-fifths of the sample
comprised women, and there was a high
prevalence of antihypertensive treatment,
diabetes, and CVD.
Clinical correlates of leptin
including relations to antecedent
BMI
Leptin was strongly correlated with BMI
at the index examination (r  0.67, P 
0.0001). More modest correlations were
noted with BMI in the decade preceding
the index examination (average of read-
ings obtained 1–10 years before baseline;
r  0.60, P  0.0001) and with BMI
10–20 years before baseline (r  0.46,
P  0.0001). Of note, BMI at the index
examination was more strongly corre-
lated (relative to leptin) with BMI in the
previous decade (r  0.93, P  0.0001)
and in the prior 10- to 20-year period (r
0.83, P  0.0001).
In multivariable analyses evaluating
the clinical correlates of log-leptin, BMI
(partial R2  0.26) and sex (partial R2 
0.28) were the strongest correlates.
Women (median 17.4 [quartile 1, quar-
tile 3: 10.6, 28.7]) had higher leptin levels
than men (7.2 [4.5, 11.4]; P 0.001), as
noted earlier. Positive associations of lep-
tin were also noted with the ratio of total-
to-HDL cholesterol (Table 2). Although
participants with diabetes (13.4 [7.9,
23.2]) had higher leptin levels in unad-
justed analyses than participants without
diabetes (12.6 [6.5, 22.4]), these differ-
ences were no longer statistically signifi-
cant upon adjustment for BMI.
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Association of leptin levels with
incidence of CHF
During a mean follow-up of 8.5 years
(range 0.2–10), 129 participants (73
women) developed CHF. Figure A1a
(available in an online appendix at http://
care.diabetesjournals.org/cgi/content/full/
dc08-1596/DC1) shows that the cu-
mulative incidence of CHF in individu-
als with leptin levels greater than or equal
to the sex-specific median value was
higher than that in individuals with leptin
levels below the median (log-rank P 
0.038). In multivariable models without
BMI, leptin was positively associated with
incident CHF (Table 3, model I). Figure
A1b (available in an online appendix) dis-
plays the results of splines relating leptin
to CHF risk: a continuous gradient of in-
creasing CHF risk is noted without evi-
dence of a threshold. However, the
association of leptin with CHF risk was
rendered nonsignificant after additional
adjustment for BMI (Table 3, model I).
Association of leptin with CVD and
hard CVD
During a mean follow-up of 7.8 years,
187 participants experienced a first CVD
event (121 women). Figure A2a (available
in an online appendix) shows a higher
cumulative incidence of CVD events in
individuals with leptin levels greater than
or equal to the sex-specific median com-
pared with participants with levels below
the median (log-rank P 0.0030). Leptin
was associated with CVD incidence in a
multivariable-adjusted model without
BMI, a finding confirmed by analysis of
splines (Fig. A2b, available in an online
appendix). However, the relations were
attenuated, becoming borderline statisti-
cally significant, upon adjustment for BMI
(Table 3, model II).
In secondary analyses, leptin levels
were also associated with hard CVD events
(141 events in, on average, 8.3 years of fol-
low-up) in multivariable-adjusted models
without BMI (hazard ratio [HR] 1.26 [95%
CI 1.04–1.52], P  0.016). However, this
association was rendered statistically non-
significant upon additional adjustment for
BMI (1.05 [0.83–1.33], P 0.70).
Based on the width of the confidence
intervals presented in Table 3, we can ex-
clude (with 95% confidence) a24% in-
crease in the hazard of developing CHF
and a51% increase in the hazard of de-
veloping CVD per 1 SD increase in sex-
standardized log-leptin in models
assessing incremental contribution of lep-
tin levels over BMI. More modest incre-
mental associations (over BMI) of leptin
with CHF and CVD outcomes would re-
quire analyses of much larger samples.
Association of leptin levels with
total mortality
During a mean follow-up of 8.0 years, 391
participants (217 women) died. The cumu-
lative incidence of death in participants did
not seem to differ for participants with lep-
tin levels more than or equal to versus less
than the sex-specific median (log-rank P
0.55) (Fig. A3a, available in an online ap-
pendix). Overall, leptin levels were not re-
lated to total mortality in multivariable
models without (HR 1.00 [95% CI 0.89–
1.12]) and with (0.97 [0.84–1.12]) adjust-
ment for BMI. Analyses of splines revealed a
U-shaped relation of log-leptin levels with
mortality (Fig. A3b, available in an online
appendix). Adding log-leptin squared into
the model confirmed a significant associa-
tion with log-leptin squared and mortality
in multivariable models without (P 
0.002) and with (P0.005) adjustment for
BMI. Given the U-shaped relation of log-
leptin and mortality, we repeated the anal-
ysis excluding participants who died within
the first year of follow-up (n  19) to ex-
clude the possibility that the association be-
tween lower leptin levels and mortality may
be due to reverse causality (i.e., comorbidity
leads to low leptin levels and is associated
with higher mortality). Our results were es-
sentially unchanged in these analyses (P
0.0099 for log-leptin squared).
To further explore the contributions
of cardiovascular versus noncardiovascu-
lar mortality to the U-shaped relations, in
post hoc analyses we examined the two
outcomes separately. On follow-up, 133
participants died of CVD and 258 of non-
CVD. In multivariable-adjusted models
including BMI, log-leptin squared was
not related to CVD death (P  0.70) but
was associated with non-CVD death (P
0.006).
Table 1—Baseline characteristics of the study sample
Characteristic Value
Clinical features
Women (%) 62.3
Age (years) 79.0  4.5
Systolic blood pressure (mmHg) 143  21
Diastolic blood pressure (mmHg) 72  11
BMI (kg/m²) 26.8  4.7
Antihypertensive treatment (%) 48.9
Current smoking (%) 8.3
Diabetes (%) 27.4
History of atrial fibrillation (%) 10.6
Prevalent heart failure (%) 5.3
History of CVD (%) 35.0
Biochemical features
Total-to-HDL cholesterol ratio (mg/dl) 4.54  1.51
Leptin (ng/ml) 12.8 (7.0, 22,7)
Log-leptin 2.51  0.81
Data are % for binary traits and means SD for continuous traits, except for leptin for which data are median
(quartile 1, quartile 3). n  818. Log, natural logarithmically transformed.
Table 2—Clinical determinants of log-leptin in elderly individuals
Variable  SE Partial R² P value
Age 0.007 0.004 0.002 0.071
Male sex 0.918 0.037 0.282 0.0001
BMI 0.094 0.004 0.257 0.0001
Total cholesterol-to-HDL ratio 0.042 0.012 0.005 0.001
History of CVD 0.070 0.038 0.002 0.067
Antihypertensive treatment 0.064 0.036 0.001 0.080
Current smoking 0.119 0.065 0.002 0.067
The regression coefficient indicates the increase in log-leptin per 1-unit increment in the predictor variable,
meaning that, e.g., a 1-unit increment in BMI leads to a 0.094-unit increase in log-leptin (1.10 in nanograms
per milliliter).
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Secondary analyses
In exploratory analyses, associations of
leptin with CHF and CVD were similar in
participants with (n  270 [33%]) and
without (data not shown) a history of obe-
sity. Likewise, a U-shaped association of
leptin with mortality was observed in
both subgroups.
CONCLUSIONS
Principal findings
First, higher circulating leptin levels were
associated with female sex and BMI. Sec-
ond, leptin levels were positively associ-
ated with incident CHF and CVD in
multivariable-adjusted models that did
not adjust for BMI. Upon additional ad-
justment for BMI, the association with
CHF was rendered nonsignificant, and
the association with CVD was borderline
significant (P  0.052). Third, we ob-
served a U-shaped relation of leptin with
total mortality driven primarily by an as-
sociation of leptin with non-CVD mortal-
ity. Finally, although leptin displayed
strong positive correlations with recent
and remote BMI, current BMI displayed
stronger correlations with past BMI (rela-
tive to leptin). These data indicate that
current BMI provides reasonable infor-
mation about the weight history of indi-
viduals, and leptin may not provide
incremental information over BMI.
The attenuation of the relations of lep-
tin to the incidence of CHF and CVD upon
adjustment for BMI can be interpreted in
several ways. Leptin may not offer incre-
mental prognostic information because of
its strong correlation with BMI. It is also
conceivable that leptin is along the causal
pathway from excess adiposity to CVD/
CHF. Indeed, an extensive body of litera-
ture supports a pathogenic role for leptin in
cardiovascular remodeling. Thus, the atten-
uation of the relations of leptin to CVD
upon adjustment for BMI may not exclude
an important pathogenic role for this adipo-
kine. Another possible interpretation is that
covariates in the models (total-to-HDL cho-
lesterol ratio, diabetes, and blood pressure)
may mediate some of the effects of leptin on
CVD risk.
The weaker association of leptin with
CHF and CVD (relative to BMI) merits
discussion. Most adults in developed
countries gain weight until their 60s and
then begin to lose weight. In humans,
obesity occurs despite higher levels of lep-
tin because of relative leptin resistance
that prevents the anorexic effects of this
hormone. Leptin resistance persists after
weight loss, so that levels may remain rel-
atively elevated compared with those in
weight-stable control subjects. Neverthe-
less, when we measured leptin in elderly
adults who are already past their peak
adult weight, it is likely that the plasma
leptin in many of them is spuriously ele-
vated compared with their “true” biologi-
cal state. In contrast, BMI reflects current
weight and is thus less likely to misclassify
elderly adults in terms of their physiolog-
ical obesity state. Also, our results under-
score the fact that BMI remains an
important predictor of CVD, notwith-
standing the pathogenic importance of
adipokines, including leptin.
Clinical correlates of leptin:
comparison with the published
literature
Our observations that BMI and female sex
are principal determinants of leptin are
consistent with findings in the literature
(15,16). Women have greater body fat
than men, and adipose tissue is a major
source of leptin, which might explain the
higher leptin levels in women. It has been
suggested that leptin captures the weight
history of individuals (12). We observed
that leptin correlated with the mean BMI
averaged over 0–10 and 10–20 years be-
fore the baseline examination. However,
leptin was not as strongly correlated with
past weight history as current BMI.
Association of leptin levels with CHF
In previous cross-sectional studies, in-
creased levels of leptin and its receptor
were reported in patients with CHF
(17,18). Furthermore, increasing evi-
dence indicates that leptin may modulate
cardiac remodeling (3). In experimental
studies, leptin exhibited a dose-
dependent inhibition of myocyte shorten-
ing in ventricular myocytes (19).
Likewise, leptin had a direct hypertrophic
effect on cultured myocytes (6). However,
some investigators have highlighted an
antihypertrophic effect of leptin (7,20).
These findings suggest that leptin has a
cardioprotective role and that increased
levels in patients with cardiac disease
might be a response to cardiac injury or
failure rather than being directly causal.
It is difficult to conclude from the
positive relations of leptin to CHF inci-
dence that leptin is an important mediator
of disease (1) or whether higher levels are
a compensatory response to underlying
cardiac remodeling. In our analysis, leptin
did not add incremental predictive infor-
mation beyond current BMI.
Association of leptin levels with
CVD and mortality
Clinical data on the association of leptin
with CVD are inconsistent. In some stud-
ies, leptin was associated with incident
myocardial infarction or coronary artery
disease (10,21), whereas other investiga-
tors did not find an association between
leptin and CHD (11).
Experimental data on leptin and vas-
cular remodeling are likewise controver-
sial, with some studies suggesting an
atherogenic effect (4,5) and other reports
indicating a vasculoprotective effect
(9,22). In our analyses, leptin was posi-
tively associated with CVD only in models
that did not include adjustment for BMI.
These data are consistent with the con-
cept that leptin may be an important me-
diator of obesity-associated CVD risk, but
it offers no incremental prognostic infor-
mation over BMI.
We observed a U-shaped relation be-
tween leptin levels and total mortality,
with low and high levels being associated
Table 3—Association of standardized log-leptin with incident outcome events: multivariable
Cox regression models without and with adjustment for BMI
Model
HR per SD increment in
log-leptin (95% CI) P value
I. Incidence of CHF (n  775 at risk)
A. Adjusting for established risk factors* 1.26 (1.03–1.55) 0.024
B. Model A and BMI 0.97 (0.75–1.24) 0.79
II. Incidence of CVD (n  532 at risk)
A. Adjusting for established risk factors† 1.28 (1.09–1.50) 0.003
B. Model A and BMI 1.23 (1.00–1.51) 0.052
SD of log-leptin in men 0.67 and in women 0.70. *Models adjusted for age, sex, systolic and diastolic
blood pressure, hypertension treatment, ratio of total-to-HDL cholesterol, diabetes, smoking, history of atrial
fibrillation, and prevalent CVD (including myocardial infarction). †Models adjusted for age, sex, systolic and
diastolic blood pressure, hypertension treatment, ratio of total-to-HDL cholesterol, diabetes, smoking, and
history of atrial fibrillation.
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with greater mortality. Such a U-shaped
relation has been described for BMI and
mortality (23,24). Additional analyses
confirmed that the U-shaped relation was
largely driven by the association of lower
and higher leptin levels with noncardio-
vascular mortality. It is conceivable that
low and high leptin levels are a marker of
greater risk of death due to noncardiovas-
cular causes (such as cancer). Such an as-
sociation would parallel the known
association of both low and high BMI with
noncardiovascular mortality, including
that due to cancer (23,25). However, the
association of leptin with mortality re-
mained U-shaped after the analyses was
restricted to individuals who survived the
first year of follow-up, suggesting that the
results are not confounded by greater
mortality risk in individuals with comor-
bidities and low leptin levels.
Limitations
We must acknowledge the limitations of
our approach. Leptin levels were deter-
mined on nonfasting blood samples, and
diurnal variations in concentrations may
result in random misclassification, which
may have biased our results toward the
null hypothesis of no association between
leptin and the outcomes evaluated. Our
data were obtained in an elderly sample of
white individuals of European ancestry.
Thus, the generalizability of our data
to other age-groups or ethnicities is
unknown.
In summary, we observed that leptin
is associated positively with incident CHF
and CVD. However, adjustment for BMI
attenuated these associations, suggesting
that leptin does not offer incremental
prognostic information over BMI. The re-
lationship of leptin with mortality was U-
shaped. Additional studies are warranted
to confirm our findings.
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